A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study - PubMed (original) (raw)
Clinical Trial
A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study
Jed G Nuchtern et al. Ann Surg. 2012 Oct.
Abstract
Objective: To demonstrate that expectant observation of young infants with small adrenal masses would result in excellent event-free and overall survival.
Background: Neuroblastoma is the most common malignant tumor in infants, and in young infants, 90% of neuroblastomas are located in the adrenal gland. Although surgical resection is standard therapy, multiple observations suggest that expectant observation could be a safe alternative for infants younger than 6 months who have small adrenal masses.
Methods: A prospective study of infants younger than 6 months with small adrenal masses and no evidence of spreading beyond the primary tumor was performed at participating Children's Oncology Group institutions. Parents could choose observation or immediate surgical resection. Serial abdominal sonograms and urinary vanillylmandelic acid and homovanillic acid measurements were performed during a 90-week interval. Infants experiencing a 50% increase in the volume of the mass, urine catecholamine values, or an increase in the homovanillic acid to vanillylmandelic acid ratio greater than 2, were referred for surgical resection.
Results: Eighty-seven eligible patients were enrolled: 83 elected observation and 4 chose immediate surgery. Sixteen observational patients ultimately had surgery; 8 had International Neuroblastoma Staging System stage 1 neuroblastoma, 2 had higher staged neuroblastoma (2B and 4S), 2 had low-grade adrenocortical neoplasm, 2 had adrenal hemorrhage, and 2 had extralobar pulmonary sequestration. The 2 patients with adrenocortical tumors were resected because of a more than 50% increase in tumor volume. The 3-year event-free survival for a neuroblastoma event was 97.7 ± 2.2% within the entire cohort of patients (n = 87). The 3-year overall survival was 100%, with a median follow-up of 3.2 years. Eighty-one percent of patients on the observation arm were spared resection.
Conclusions: Expectant observation of infants younger than 6 months with small adrenal masses led to excellent event-free survival and overall survival while avoiding surgical intervention in a large majority of the patients.
Trial registration: ClinicalTrials.gov NCT00445718.
Figures
Figure 1
Event-free survival for a “neuroblastoma event” (EFSNE), event-free survival for “any malignancy event” (EFSAME), and overall survival for 87 eligible patients. The number of patients at risk for event at the start of Years 3 and 6 appear along each curve. Note that the y-axis of the survival plots begins at 60%, not 0%.
Figure 2
Resection-free survival (RFS) for 83 patients on the observation arm of the study. The number of patients at risk for event at the start of Years 3 and 6 appear along the curve. Note that the y-axis of the survival plots begins at 60%, not 0%.
Similar articles
- Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.
Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J. Nickerson HJ, et al. J Clin Oncol. 2000 Feb;18(3):477-86. doi: 10.1200/JCO.2000.18.3.477. J Clin Oncol. 2000. PMID: 10653863 Clinical Trial. - Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.
Okazaki T, Kohno S, Mimaya J, Hasegawa S, Urushihara N, Yoshida A, Kawano S, Kusafuka J, Horikoshi Y, Takashima Y, Aoki K, Hamazaki M. Okazaki T, et al. Pediatr Surg Int. 2004 Jan;20(1):27-32. doi: 10.1007/s00383-003-1070-x. Epub 2003 Dec 19. Pediatr Surg Int. 2004. PMID: 14689211 - Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: does it affect the clinical course?
Guglielmi M, De Bernardi B, Rizzo A, Federici S, Boglino C, Siracusa F, Leggio A, Cozzi F, Cecchetto G, Musi L, Bardini T, Fagnani AM, Bartoli GC, Pampaloni A, Rogers D, Conte M, Milanaccio C, Bruzzi P. Guglielmi M, et al. J Clin Oncol. 1996 May;14(5):1537-44. doi: 10.1200/JCO.1996.14.5.1537. J Clin Oncol. 1996. PMID: 8622069 Clinical Trial. - Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.
Peinemann F, van Dalen EC, Enk H, Berthold F. Peinemann F, et al. Cochrane Database Syst Rev. 2017 Aug 25;8(8):CD010685. doi: 10.1002/14651858.CD010685.pub3. Cochrane Database Syst Rev. 2017. PMID: 28840597 Free PMC article. Review. - Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation.
Peinemann F, van Dalen EC, Tushabe DA, Berthold F. Peinemann F, et al. Cochrane Database Syst Rev. 2015 Jan 29;1:CD010685. doi: 10.1002/14651858.CD010685.pub2. Cochrane Database Syst Rev. 2015. PMID: 25634649 Updated. Review.
Cited by
- Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma.
Mao C, Poimenidou M, Craig BT. Mao C, et al. Cancers (Basel). 2024 Aug 17;16(16):2865. doi: 10.3390/cancers16162865. Cancers (Basel). 2024. PMID: 39199637 Free PMC article. Review. - Mature Cystic Teratoma in a Newborn With Down Syndrome.
Poyyamozhy KI, Srirampur S, Kumbha P, Kumbha N. Poyyamozhy KI, et al. Cureus. 2024 Jul 5;16(7):e63878. doi: 10.7759/cureus.63878. eCollection 2024 Jul. Cureus. 2024. PMID: 39099946 Free PMC article. - Extracting Electronic Health Record Neuroblastoma Treatment Data With High Fidelity Using the REDCap Clinical Data Interoperability Services Module.
Furner B, Cheng A, Desai AV, Benedetti DJ, Friedman DL, Wyatt KD, Watkins M, Volchenboum SL, Cohn SL. Furner B, et al. JCO Clin Cancer Inform. 2024 May;8:e2400009. doi: 10.1200/CCI.24.00009. JCO Clin Cancer Inform. 2024. PMID: 38815188 Free PMC article. - The Neuroblastoma Microenvironment, Heterogeneity and Immunotherapeutic Approaches.
Polychronopoulos PA, Bedoya-Reina OC, Johnsen JI. Polychronopoulos PA, et al. Cancers (Basel). 2024 May 13;16(10):1863. doi: 10.3390/cancers16101863. Cancers (Basel). 2024. PMID: 38791942 Free PMC article. Review. - Clinical features and treatment options for pediatric adrenal incidentalomas: a retrospective single center study.
Zhu X, Liu S, Yuan Y, Gu N, Sha J, Guo Y, Deng Y. Zhu X, et al. BMC Pediatr. 2024 Mar 16;24(1):186. doi: 10.1186/s12887-024-04673-7. BMC Pediatr. 2024. PMID: 38491421 Free PMC article.
References
- Gutierrez JC, Fischer AC, Sola JE, et al. Markedly improving survival of neuroblastoma: a 30-year analysis of 1,646 patients. Pediatr Surg Int. 2007;23:637–646. - PubMed
- Nitschke R, Smith EI, Shochat S, et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. J Clin Oncol. 1988;6:1271–1279. - PubMed
- De BB, Conte M, Mancini A, et al. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol. 1995;13:884–893. - PubMed
- Evans AE, Silber JH, Shpilsky A, et al. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol. 1996;14:2504–2510. - PubMed
- Ikeda H, Suzuki N, Takahashi A, et al. Surgical treatment of neuroblastomas in infants under 12 months of age. J Pediatr Surg. 1998;33:1246–1250. - PubMed
Publication types
MeSH terms
Grants and funding
- U10 CA98413/CA/NCI NIH HHS/United States
- UO1 CA098543/CA/NCI NIH HHS/United States
- U10 CA098413/CA/NCI NIH HHS/United States
- U10 CA098543/CA/NCI NIH HHS/United States
- U10 CA98543/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical